Association of HLA types A1-B8-DR3 and B27 with rapid and slow progression of HIV disease

QJM: An International Journal of Medicine

Volumn 89, Issue 3, 1996, Pages 177-185

  McNeil, A J ^a   Yap, P L ^b   Gore, S M ^c   Brettle, R P ^d   McColl, M ^b   Wyld, R ^d   Davidson, S ^b   Weightman, R ^d   Richardson, A M ^d   Robertson, J R ^e  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b Edinburgh S E Scotland Blood T   (United Kingdom)

^c MRC BIOSTATISTICS UNIT   (United Kingdom)

^d CITY HOSPITAL   (United Kingdom)

^e Muirhouse Medical Group   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; HLA A1 ANTIGEN; HLA B27 ANTIGEN; HLA B8 ANTIGEN; HLA DR3 ANTIGEN;

ADOLESCENT; ADULT; ARTICLE; DISEASE COURSE; DRUG ABUSE; FEMALE; GROWTH CURVE; HLA TYPING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK; SEROCONVERSION;

EID: 13344293690     PISSN: 00335622     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/89.3.177     Document Type: Article

References (27)

1. Steel CM, Ludlam CA, Beatson D, Peutherer JF, Cuthbert RJC, Simmonds P, Morrison H, Jones M. HLA haplotype A1 B8 DR3 as a risk factor for HIV-related disease. Lancet 1988; 1:1185-8.
2. Kaslow RA, Duquesnoy R, VanRaden M, Kingsley L, Marrari M, Friedman H, Su S, Saah AJ, Detels R, Phair J, Rinaldo C. A1, Cw7, B8, DR3 HLA antigen combination associated with rapid decline of T-helper ymphocytes in HIV-1 infection. Lancet 1990; 335:927-30.
3. Kaplan C, Muller JY, Doinel C, Lefrere JJ, Paquez F, Roger P, Salmon D, Salmon C. HLA-associated susceptibility to acquired immune deficiency syndrome in HIV-1-seropositive subjects. Hum Hered 1990; 40:290-8.
4. Ohno S. How cytotoxic T cells manage to discriminate nonself from self at the nonapeptide level. Proc Natl Acad Sci USA 1992; 89:4643-7.
5. McNeil AJ. Statistical methods in AIDS progression studies with an analysis of the Edinburgh City Hospital cohort. PhD thesis, University of Cambridge, 1993.
6. Robertson JR, Bucknall ABV, Welsby PD, Roberts JJK, Inglis JM, Peutherer JF, Brettle RP. An epidemic of Aids-related virus (HTLV-III/LAV) infection amongst intravenous drug abusers in a Scottish general practice. Br Med J 1986; 292:527-30.
7. Brettle RP & Nelles B. Special Problems of injecting drug misusers. Br Med Bull 1988; 44:149-60.
8. Brettle RP, Bisset K, Burns S, et al. Human immunodeficiency virus and drug misuse - The Edinburgh experience. Br Med J 1987; 295:421-4.
9. Bisset C, Jones G, Davidson J, Cummins B, Burns S, Inglis JM, Brettle RP. Mobility of injection drug users and transmission of HIV. Lancet 1989; ii:44.
10. Brettle RP, McNeil AJ, Gore SM, Bird AG, Leen CSL, Richardson A. The Edinburgh City Hospital cohort: analysis of enrolment, progression and mortality by baseline covariates. Q J Med 1995; 88:479-91.
11. Burns S, Brettle RP, Gore SM, Peutherer J, Robertson JR. Epidemiology of injection drug use related HIV in Edinburgh: a historical perspective and new insight on past HIV incidence from the retrospective HIV testing of stored sera. J Infect 1996 (in press).
12. Terasaki PI, ed. Histocompatibility testing 1980. Los Angeles, UCLA Press, 1980.
13. Cox DR, Oakes D. Analysis of Survival Data. London, Chapman and Hall, 1984.
14. McNeil AJ, Gore SM. Statistical analysis of zidovudine (AZT) effect on CD4 cell counts in HIV disease. Statistics Med 1996; 15:75-92.
15. McNeil AJ. Bayes estimates for immunological progression rates in HIV disease. Technical Report, Applied Mathematics, University of Zurich.
16. Lange N, Carlin BP, Gelfand AE. Hierarchical Bayes models for the progression of HIV infection using longitudinal CD4 T-cell numbers. J Am Statist Assoc 1992; 87:615-26.
17. Goldstein H. Multilevel Statistical Models. Arnold, 1995.
18. MAP Workshop. Marker Paths. Statistics Med 1993; 12:2099-126.
19. Jazwinska EC & Kilpatrick DC. Haplotype frequencies in south-east Scotland. Tissue Antigens 1987; 29:115-19.
20. Brookmeyer R, Gail MH, Polk BF. The prevalent cohort study and the acquired immunodeficiency syndrome. Am J Epidemiol 1987; 126:14-24.
21. Lee CA, Webster A, Griffiths PD & Kernoff PBA. Symptomless HIV infection after more than 10 years. Lancet 1990; i:425-6.
22. Learmonth J, Tindall B, Evans L, Cunningham A, Cunningham P, Wells J, Penny R, Kaldor J & Cooper DA. Long term symptomless HIV-1 infection in recipients of blood products from a single donor. Lancet 1992; 340:863-7.
23. Buchbinder S, Mann D, Louie L, Viliinger F, Katz M, Holmberg S, et al. Healthy long term positives (HLPs): genetic cofactors for delayed HIV disease progression. IX International Conference on AIDS, Berlin 1993: Abstract WS-B03-2.
24. Sestak P, Montaner JSG, Craib KJP, Le TN, O'Shaughnessy MV, Schecter MT. Long term survival without significant HIV associated clinical or laboratory effects in a cohort of gay men. IX International Conference on AIDS, Berlin 1993: Abstract PO-C04-2660.
25. Hounsell EF, Renouf DV, Liey D, Dalgleish AG, Habeshaw JA. A proposed molecular model for the carboxyterminus of HIV-1 p120 showing structural feature consistent with the presence of a T cel alloepitope. Mol Aspects Med 1991; 12:283-96.
26. Geluk A, Elferink DG, Slierendregt BL, Van Weijgaarden KE, DeVries RRP, Ottenhoff THM, Bontrop RE. Evolutionary conservation of major histocompatibility complex DR/peptide/T cell interactions in primates. J Exp Med 1993; 177: in press.
27. Wilson S, Hounsell E, Habeshaw JA. Generation of autoand allo-cytotoxic T cell responses by regions of HIV-1 gp120/41 which share structural homology with human class 1/2 molecules. IX International Conference on AIDS, Berlin 1993: Abstract PO-A19-0371.